MedTrace Logo

TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)

NCT02608411 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-10-13

No results posted yet for this study

Summary

This study aims to assess the role of MET inhibitors as maintenance treatment in adult patients with extensive stage small cell lung cancer.

Conditions

  • Carcinoma, Small Cell

Interventions

DRUG

ARQ197

Sponsors & Collaborators

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Principal Investigators

  • Giulia Pasello, MD · Istituto Oncologico Veneto IRCCS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-19
Primary Completion
2017-02-21
Completion
2017-02-21

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02608411 on ClinicalTrials.gov